MLN 0415
Alternative Names: MLN0415; SAR 479746Latest Information Update: 05 Nov 2023
At a glance
- Originator Millennium Pharmaceuticals
- Developer Takeda
- Class Anti-inflammatories; Small molecules
- Mechanism of Action I-kappa B kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arthritis; Inflammation
Most Recent Events
- 14 May 2008 Takeda acquires Millennium
- 30 Aug 2006 Phase-I clinical trials in Inflammation in USA (PO)
- 02 Nov 2005 Preclinical trials in Inflammation in USA (PO)